Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ovine enoxaparin
- Development stage
- Phase 4
- Lead developer
- Metiska Farma
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intravenous
01
Overview
Ovine enoxaparin is a low molecular weight heparin (LMWH) anticoagulant derived from sheep (ovine) sources, as opposed to the traditional porcine-derived enoxaparin. It functions by enhancing the inhibition of coagulation factors Xa and IIa (thrombin), primarily through antithrombin III, thereby reducing blood clot formation. Ovine enoxaparin has been shown in clinical studies to be pharmacodynamically equivalent to porcine-derived enoxaparin (such as Lovenox), with similar anti-FXa and anti-FIIa activity, safety, and tolerability profiles after subcutaneous administration in healthy volunteers. The drug is intended for use in the prevention and treatment of thromboembolic disorders such as deep vein thrombosis and pulmonary embolism[7].
- Brand names
- Antiten-A
- Other names
- ovine enoxaparin sodium
02
Targets
F2 (Thrombin)ATIII (Antithrombin III)F10 (Factor Xa)
Beyond the preview
Go deeper on ovine enoxaparin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ovine enoxaparin.